The ACR’s new RISE Registry, set for 2026, will be a modern productivity tool with new analytics, easy EHR connection & robust research data.
ACR Advocacy Update 2025, Federal & State
ACR representatives outlined its 2025 legislative priorities, including fixing the MPFS, reforming prior authorization & protecting telehealth reimbursement.
As Understanding of Long COVID Deepens, the Search for Therapies Continues
Experts discussed causes of long COVID & potential therapies at this ACR Convergence 2025 session.
No Longer as Vexing: The Role of Somatic Mutations in Rheumatic Diseases
At this ACR Convergence 2025 session, two experts discussed VEXAS & the role that genetic sequencing should play in the practice of a rheumatologist.
Collaboration Is Key to Oral Health in Scleroderma & Sjögren’s Disease
At this ACR Convergence 2025 session, experts discussed the oral manifestations of scleroderma & Sjögren’s disease & the importance of dentists & rheumatologists working together.
The Microbiome’s Impact on Rheumatoid Arthritis & Drug Response
The gut microbiome may trigger RA & predict methotrexate response. ACR Convergence 2025 experts discuss pathogenesis & drug efficacy.
Differentiating POTS from Other Conditions
At a ACR Convergence 2025 session, two experts discussed POTS, the importance of considering dysautonomia when making a differential diagnosis & an interdisciplinary approach to treatment.
The Pros & Cons of AI
As the uses for artificial intelligence grow within rheumatology, so do the benefits and the concerns about the technology. In a session at ACR Convergence 2025, two experts discuss the research on both sides of the debate.
Lupus Nephritis: A Serious Manifestation of Systemic Lupus Erythematosus
In this review, some of the many abstracts on research into lupus nephritis presented at ACR Convergence 2025 are highlighted. The abstracts selected demonstrate the advances made on the early recognition of the condition, as well as offering some hope in terms of achieving better outcomes.
Lupus Nephritis from Bench to Bedside
Urinary biomarkers may have the potential to detect early treatment responses or failures in patients with lupus nephritis, according to Andrea Fava, MD. He and other experts discussed the latest research into lupus nephritis and how apply the recent ACR guideline to refractory cases.
- 1
- 2
- 3
- …
- 329
- Next Page »